Adimmune Corp (4142) - Total Assets
Based on the latest financial reports, Adimmune Corp (4142) holds total assets worth NT$8.38 Billion TWD (≈ $264.03 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Adimmune Corp cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Adimmune Corp - Total Assets Trend (2007–2024)
This chart illustrates how Adimmune Corp's total assets have evolved over time, based on quarterly financial data. See 4142 net assets for net asset value and shareholders' equity analysis.
Adimmune Corp - Asset Composition Analysis
Current Asset Composition (December 2024)
Adimmune Corp's total assets of NT$8.38 Billion consist of 42.6% current assets and 57.4% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 27.6% |
| Accounts Receivable | NT$187.81 Million | 2.2% |
| Inventory | NT$627.99 Million | 7.4% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$47.86 Million | 0.6% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2007–2024)
This chart illustrates how Adimmune Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 4142 stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Adimmune Corp's current assets represent 42.6% of total assets in 2024, an increase from 14.2% in 2007.
- Cash Position: Cash and equivalents constituted 27.6% of total assets in 2024, up from 2.3% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 18.0% in 2007.
- Asset Diversification: The largest asset category is inventory at 7.4% of total assets.
Adimmune Corp Competitors by Total Assets
Key competitors of Adimmune Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Adimmune Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.85 | 3.28 | 9.61 |
| Quick Ratio | 1.42 | 2.54 | 9.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$1.55 Billion | NT$2.60 Billion | NT$4.52 Billion |
Adimmune Corp - Advanced Valuation Insights
This section examines the relationship between Adimmune Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.87 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -10.6% |
| Total Assets | NT$8.48 Billion |
| Market Capitalization | $219.78 Million USD |
Valuation Analysis
Below Book Valuation: The market values Adimmune Corp's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Adimmune Corp's assets decreased by 10.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Adimmune Corp (2007–2024)
The table below shows the annual total assets of Adimmune Corp from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$8.48 Billion ≈ $267.21 Million |
-10.58% |
| 2023-12-31 | NT$9.48 Billion ≈ $298.81 Million |
+3.67% |
| 2022-12-31 | NT$9.15 Billion ≈ $288.23 Million |
+14.21% |
| 2021-12-31 | NT$8.01 Billion ≈ $252.36 Million |
-5.47% |
| 2020-12-31 | NT$8.47 Billion ≈ $266.96 Million |
+28.97% |
| 2019-12-31 | NT$6.57 Billion ≈ $207.00 Million |
+15.71% |
| 2018-12-31 | NT$5.68 Billion ≈ $178.90 Million |
-1.18% |
| 2017-12-31 | NT$5.75 Billion ≈ $181.03 Million |
-15.31% |
| 2016-12-31 | NT$6.78 Billion ≈ $213.76 Million |
+24.85% |
| 2015-12-31 | NT$5.43 Billion ≈ $171.22 Million |
-7.21% |
| 2014-12-31 | NT$5.86 Billion ≈ $184.53 Million |
+6.75% |
| 2013-12-31 | NT$5.49 Billion ≈ $172.85 Million |
-8.46% |
| 2012-12-31 | NT$5.99 Billion ≈ $188.83 Million |
+6.87% |
| 2011-12-31 | NT$5.61 Billion ≈ $176.69 Million |
+3.53% |
| 2010-12-31 | NT$5.42 Billion ≈ $170.67 Million |
-5.11% |
| 2009-12-31 | NT$5.71 Billion ≈ $179.85 Million |
+36.13% |
| 2008-12-31 | NT$4.19 Billion ≈ $132.11 Million |
+95.64% |
| 2007-12-31 | NT$2.14 Billion ≈ $67.53 Million |
-- |
About Adimmune Corp
Adimmune Corporation engages in the development, manufacture, and distribution of vaccines and other biological products in Taiwan, the United States, China, and internationally. The company offers AdimFlu-S, a quadrivalent influenza vaccine; suspensions for injection influenza vaccines; and tetanus toxoid alum precipitated product for the prevention of tetanus after injury. It also develops Adim… Read more